Skip to main content
رجوع
ARWR logo

Arrowhead Pharmaceuticals, Inc.

جودة البيانات: 100%
ARWR
NASDAQ Healthcare Biotechnology
KWD 56.27
▼ KWD 0.40 (-0.71%)
القيمة السوقية: 7.88B
نطاق اليوم
KWD 55.01 KWD 56.88
نطاق 52 أسبوعًا
KWD 9.57 KWD 76.76
حجم التداول
1,868,416
متوسط 50 يوم / 200 يوم
KWD 63.61 / KWD 41.41
الإغلاق السابق
KWD 56.67

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -4831.2 0.4
P/B 16.9 2.9
ROE % -0.5 3.9
Net Margin % -0.2 3.8
Rev Growth 5Y % 56.5 10.0
D/E 0.8 0.2

السعر المستهدف للمحللين

Hold
KWD 78.780 +40.0%
Low: KWD 35.000 High: KWD 110.000
ربحية السهم المستقبلية
-KWD 3.211
الإيرادات المقدّرة
450 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 3.013
KWD 1.520 – KWD 4.653
1.6 B 5
FY2029 -KWD 1.268
-KWD 1.958 – -KWD 0.640
890 M 2
FY2028 -KWD 2.812
-KWD 4.101 – -KWD 1.097
550 M 7

النقاط الرئيسية

Revenue grew 56.50% annually over 5 years — strong growth
Generating 156.89M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 23201.65%
Capital efficient — spends only 2.73% of revenue on capex
Interest coverage of 1.10× — tight debt servicing

النمو

Revenue Growth (5Y)
56.50%
Revenue (1Y)23258.15%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-0.50%
ROIC8.86%
Net Margin-0.20%
Op. Margin11.86%

الأمان

Debt / Equity
0.79
Current Ratio4.86
Interest Coverage1.10

التقييم

P/E Ratio
-4831.15
P/B Ratio16.91
EV/EBITDA81.54
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 23258.15% Revenue Growth (3Y) 85.62%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 56.50% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 829.45M Net Income (TTM) -1.63M
ROE -0.50% ROA -0.12%
Gross Margin 97.12% Operating Margin 11.86%
Net Margin -0.20% Free Cash Flow (TTM) 156.89M
ROIC 8.86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.79 Current Ratio 4.86
Interest Coverage 1.10 Dividend Yield 0.00%
Valuation
P/E Ratio -4831.15 P/B Ratio 16.91
P/S Ratio 9.50 PEG Ratio 28.35
EV/EBITDA 81.54 Dividend Yield 0.00%
Market Cap 7.88B Enterprise Value 8.02B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 829.45M 3.55M 240.74M 243.23M 138.29M
Net Income -1.63M -599.49M -205.28M -176.06M -140.85M
EPS (Diluted) -0.01 -5.00 -1.92 -1.67 -1.36
Gross Profit 805.52M 3.55M 240.74M 243.23M 138.29M
Operating Income 98.35M -601.08M -205.00M -178.51M -149.04M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.39B 1.14B 765.55M 691.94M 710.15M
Total Liabilities 881.88M 948.74M 478.39M 273.60M 301.33M
Shareholders' Equity 466.05M 185.44M 271.34M 398.52M 408.82M
Total Debt 366.28M 851.91M 383.50M 81.58M 25.55M
Cash & Equivalents 226.55M 102.69M 110.89M 108.01M 184.43M
Current Assets 950.64M 695.47M 419.52M 405.30M 384.60M
Current Liabilities 195.49M 103.17M 105.46M 138.85M 146.54M